RecruitingNot ApplicableNCT07281001
A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
Sponsor
Blokhin's Russian Cancer Research Center
Enrollment
60 participants
Start Date
Dec 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria4
- Patients aged over 18 years old.
- Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- Patients has received Trastuzumab Deruxtecan
- Available medical history.
Exclusion Criteria2
- Incomplete medical history.
- Pregnancy or breast-breeding
Interventions
DRUGT-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.
T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07281001
Related Trials
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT0104237942 locations
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT0710238121 locations
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
NCT074596737 locations
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT048865314 locations
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT053256321 location